Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jan 2026 Planned End Date changed from 30 Sep 2029 to 31 Oct 2029.
05 Jan 2026 Planned primary completion date changed from 30 Sep 2029 to 31 Oct 2029.
04 Sep 2025 According to a Roche media release, Susvimo (ranibizumab injection, 100 mg/mL) is currently under review by the European Medicines Agency (EMA) for the treatment of neovascular age-related macular degeneration (nAMD). The EMA's evaluation is based on data from the pivotal Phase III Archway trial, the Phase II LADDER study, and an open-label long-term extension study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com